Back to the main directory
EarningsReview / Equity
- Melco Resorts (MLCO US) by HSBC
- Terminix: Q1 results and read across by BNP Paribas Exane
- Results well up but the context remains uncertain by BNP Paribas Exane
- Guidance confirmed but high uncertainty remains by BNP Paribas Exane
- Pandora - US woes outweighed by RoW and valuation by Danske Bank Equity Research
- Loomis - Growth at the expense of margins by Danske Bank Equity Research
- Digital Workforce - Showing progress – but also temporary headwinds by Danske Bank Equity Research
- Outokumpu - Attractive valuation despite nearing peak earnings by Danske Bank Equity Research
- Aker ASA - Buy/NOK 1,200 (1,100): Going full throttle by Nordea
- Equinor - Hold: Firing on all cylinders – as expected by Nordea
- Multiconsult - Buy/NOK 180: Flying start to 2022 but market appears riskier by Nordea
- Pandora - Hold (Buy/DKK 900): Limited triggers ahead by Nordea
- Renewcell - Buy/SEK 300 (370): New capacity on schedule but capex level raised by Nordea
- Sampo - Buy/EUR 52 (51): Stay long as rates increase by Nordea
- Storebrand - Buy/NOK 101: Capital distribution and improved visibility by Nordea
- Schibsted (Buy, TP: NOK350.00) - Relief warranted by DnB Markets
- Elektroimportøren (Buy, TP: NOK93.00) - Soft Q1 and guidance by DnB Markets
- Wihlborgs (Buy, TP: SEK195.00) - Another solid quarter by DnB Markets
- Klaveness Combination Carriers (Buy, TP: NOK84.00) - Firing on all cylinders by DnB Markets
- Skanska (Buy, TP: SEK215.00) - Risks confirmed, upside returns by DnB Markets
- Gentian Diagnostics (Buy, TP: NOK92.00) - Growth, but NT-proBNP concerns by DnB Markets
- OPAP - Progressing the strategy by Edison Investment Research
- BerGenBio - Focusing in on 1L NSCLC and COVID-19 by Edison Investment Research
- Challenging cross-currents and taken out with the tide by BNP Paribas Exane
- Marico Industries (MRCO IN) by HSBC